{"id":1007455,"date":"2026-10-01T08:29:36","date_gmt":"2026-10-01T12:29:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\/"},"modified":"2026-10-01T08:29:36","modified_gmt":"2026-10-01T12:29:36","slug":"harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\/","title":{"rendered":"Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days"},"content":{"rendered":"
\n

PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia. This poster will be presented at the 17th European Narcolepsy Days, taking place October 2\u20133, 2026, in Bern, Switzerland.<\/p>\n

Poster details are listed below:<\/p>\n\n\n\n\n
\n Abstract Title<\/strong>:<\/td>\n\n Phase 3, randomized, double-blind, placebo-controlled studies of HBS-301 for narcolepsy and idiopathic hypersomnia<\/em>\n <\/td>\n<\/tr>\n
\n Date\/Times<\/strong>:<\/td>\nOctober 2, 16:30 (CEST)
October 3, 12:30 (CEST)<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n About HBS-301\u00a0
<\/strong>HBS-301 is an investigational, optimized, high-dose formulation of enteric-coated pitolisant tablets. HBS-301 is being developed in multiple tablet strengths up to 60 mg to treat excessive daytime sleepiness and other symptoms in patients with narcolepsy or idiopathic hypersomnia (IH). HBS-301 is currently being evaluated in two phase 3 clinical trials. The ONSTRIDE-1 study in adult patients with narcolepsy and the ONSTRIDE-2 study in adult patients with IH.\u00a0<\/p>\n

\n About Harmony Biosciences<\/strong>
\n
Harmony Biosciences\u00a0is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked,\u00a0Harmony Biosciences\u00a0is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by\u00a0Paragon Biosciences, LLC, in 2017 and headquartered in\u00a0Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit\u00a0www.harmonybiosciences.com<\/a>.<\/p>\n

\n Harmony Biosciences Investor Contact:<\/strong>
\n
Brennan Doyle
484-566-3685
bdoyle@harmonybiosciences.com<\/a><\/p>\n

\n Harmony Biosciences Media Contact:<\/strong>
\n
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia. This poster will be presented at the 17th European Narcolepsy Days, taking place October 2\u20133, 2026, in Bern, Switzerland. Poster details are listed below: Abstract Title: Phase 3, randomized, double-blind, placebo-controlled studies of HBS-301 for narcolepsy and idiopathic hypersomnia Date\/Times: October 2, 16:30 (CEST)October 3, 12:30 (CEST) \u00a0 \u00a0 About HBS-301\u00a0HBS-301 is an investigational, optimized, high-dose formulation of enteric-coated pitolisant tablets. HBS-301 is being developed in multiple tablet strengths up to 60 mg to treat excessive daytime sleepiness … <\/p>\n

Continue reading “Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1007455","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nHarmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia. This poster will be presented at the 17th European Narcolepsy Days, taking place October 2\u20133, 2026, in Bern, Switzerland. Poster details are listed below: Abstract Title: Phase 3, randomized, double-blind, placebo-controlled studies of HBS-301 for narcolepsy and idiopathic hypersomnia Date\/Times: October 2, 16:30 (CEST)October 3, 12:30 (CEST) \u00a0 \u00a0 About HBS-301\u00a0HBS-301 is an investigational, optimized, high-dose formulation of enteric-coated pitolisant tablets. HBS-301 is being developed in multiple tablet strengths up to 60 mg to treat excessive daytime sleepiness … Continue reading "Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-01T12:29:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzQ3NiM3ODcyNzM5IzIyMDE1NTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days\",\"datePublished\":\"2026-10-01T12:29:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\\\/\"},\"wordCount\":295,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNzQ3NiM3ODcyNzM5IzIyMDE1NTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\\\/\",\"name\":\"Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNzQ3NiM3ODcyNzM5IzIyMDE1NTM=\",\"datePublished\":\"2026-10-01T12:29:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNzQ3NiM3ODcyNzM5IzIyMDE1NTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNzQ3NiM3ODcyNzM5IzIyMDE1NTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\/","og_locale":"en_US","og_type":"article","og_title":"Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days - Market Newsdesk","og_description":"PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia. This poster will be presented at the 17th European Narcolepsy Days, taking place October 2\u20133, 2026, in Bern, Switzerland. Poster details are listed below: Abstract Title: Phase 3, randomized, double-blind, placebo-controlled studies of HBS-301 for narcolepsy and idiopathic hypersomnia Date\/Times: October 2, 16:30 (CEST)October 3, 12:30 (CEST) \u00a0 \u00a0 About HBS-301\u00a0HBS-301 is an investigational, optimized, high-dose formulation of enteric-coated pitolisant tablets. HBS-301 is being developed in multiple tablet strengths up to 60 mg to treat excessive daytime sleepiness … Continue reading \"Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-01T12:29:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzQ3NiM3ODcyNzM5IzIyMDE1NTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days","datePublished":"2026-10-01T12:29:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\/"},"wordCount":295,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzQ3NiM3ODcyNzM5IzIyMDE1NTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\/","name":"Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzQ3NiM3ODcyNzM5IzIyMDE1NTM=","datePublished":"2026-10-01T12:29:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzQ3NiM3ODcyNzM5IzIyMDE1NTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzQ3NiM3ODcyNzM5IzIyMDE1NTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcolepsy-days\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1007455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1007455"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1007455\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1007455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1007455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1007455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}